| Literature DB >> 32713384 |
Isaac Chun-Hai Fung1, Chi-Ngai Cheung2, Andreas Handel3.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic prompted universities across the United States to close campuses in Spring 2020. Universities are deliberating whether, when, and how they should resume in-person instruction in Fall 2020. In this essay, we discuss some practical considerations for the use of 2 potentially useful control strategies based on testing: (1) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction (RT-PCR) testing followed by case-patient isolation and quarantine of close contacts, and (2) serological testing followed by an "immune shield" approach, that is, low social distancing requirements for seropositive persons. The isolation of case-patients and quarantine of close contacts may be especially challenging, and perhaps prohibitively difficult, on many university campuses. The "immune shield" strategy might be hobbled by a low positive predictive value of the tests used in populations with low seroprevalence. Both strategies carry logistical, ethical, and financial implications. The main nonpharmaceutical interventions will remain methods based on social distancing (eg, capping class size) and personal protective behaviors (eg, universal facemask wearing in public space) until vaccines become available, or unless the issues discussed herein can be resolved in such a way that using mass testing as main control strategies becomes viable.Entities:
Keywords: communicable diseases; digital health; epidemics; infectious disease transmission; social media
Year: 2020 PMID: 32713384 PMCID: PMC7450242 DOI: 10.1017/dmp.2020.266
Source DB: PubMed Journal: Disaster Med Public Health Prep ISSN: 1935-7893 Impact factor: 1.385
Advantages and Disadvantages of Mass RT-PCR Testing for SARS-CoV-2 and Mass Serological Testing for Antibodies Against SARS-CoV-2
| Testing | Pros | Cons |
|---|---|---|
| RT-PCR testing | Identify individuals currently infected with SARS-CoV-2 including asymptomatic individuals | Expensive |
| Serological testing for antibodies | Identify individuals who have antibodies and who might be immune to reinfection | Expensive |